A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Condition:   Stage III Non-small-cell Lung Cancer Interventions:   Drug: TQB2450;   Drug: Anlotinib;   Drug: TQB2450(blank);   Drug: Anlotinib(blank) Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials